Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""lapatinib"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 3526
Tytuł:
EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells.
Autorzy:
Achounna AS; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Ordaz-Rosado D; Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
García-Quiroz J; Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
Morales-Guadarrama G; Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
Milo-Rocha E; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Larrea F; Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
Díaz L; Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Tlalpan, Ciudad de México 14080, Mexico.
García-Becerra R; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.; Programa de Investigación de Cáncer de Mama, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 09; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 09.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/metabolism
Calcitriol/*analogs & derivatives
Humans ; Female ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Calcitriol/pharmacology ; Estrogen Receptor alpha/genetics ; Estrogen Receptor alpha/metabolism ; Estrogen Receptor Modulators/pharmacology ; Proto-Oncogene Proteins c-akt/metabolism ; Receptor, ErbB-2/metabolism ; Estrogen Antagonists/therapeutic use ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Autorzy:
Fonseca-Alves CE; Department of Veterinary Surgery and Animal Reproduction, São Paulo State University-UNESP, Botucatu-SP, Brazil.; Institute of Health Sciences, Paulista University-UNIP, Bauru-SP, 17048-290, Brazil.
Leis-Filho AF; Department of Veterinary Surgery and Animal Reproduction, São Paulo State University-UNESP, Botucatu-SP, Brazil.
Lacerda ZA; Department of Veterinary Surgery and Animal Reproduction, São Paulo State University-UNESP, Botucatu-SP, Brazil.
de Faria Lainetti P; Department of Veterinary Surgery and Animal Reproduction, São Paulo State University-UNESP, Botucatu-SP, Brazil.
Amorim RL; Department of Veterinary Clinic, São Paulo State University-UNESP, Botucatu-SP, 18618-681, Brazil.
Rogatto SR; Department of Clinical Genetics, University Hospital of Southern Denmark, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Apr 02; Vol. 19 (4), pp. e0297043. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Breast Neoplasms*/pathology
Prostatic Neoplasms*/drug therapy
Prostatic Neoplasms*/genetics
Male ; Humans ; Animals ; Dogs ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Receptor, ErbB-2/metabolism ; Quinazolines/pharmacology ; Quinazolines/therapeutic use ; Apoptosis ; Cell Line, Tumor ; Drug Resistance, Neoplasm
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.
Autorzy:
Bonomi M; Oncology Unit, ASST Cremona, 26100 Cremona, Italy.
Spada D; Oncology Unit, ASST Cremona, 26100 Cremona, Italy.
Baiocchi GL; Department of Surgery, ASST Cremona, 26100 Cremona, Italy.
Celotti A; Department of Surgery, ASST Cremona, 26100 Cremona, Italy.
Brighenti M; Oncology Unit, ASST Cremona, 26100 Cremona, Italy.
Grizzi G; Oncology Unit, ASST Cremona, 26100 Cremona, Italy.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 30; Vol. 25 (7). Date of Electronic Publication: 2024 Mar 30.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Adenocarcinoma*/drug therapy
Adenocarcinoma*/genetics
Circulating Tumor DNA*
Humans ; Trastuzumab/therapeutic use ; Ado-Trastuzumab Emtansine ; Lapatinib
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports.
Autorzy:
Yanase Y; Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-Shi, Ibaraki, 305-8576, Japan.
Bando H; Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennnodai, Tsukuba-Shi, Ibaraki, 305-8575, Japan. .
Sato R; Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-Shi, Ibaraki, 305-8576, Japan.
Matsuo T; Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-Shi, Ibaraki, 305-8576, Japan.
Ueda A; Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-Shi, Ibaraki, 305-8576, Japan.
Okazaki M; Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba-Shi, Ibaraki, 305-8576, Japan.
Hashimoto S; Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennnodai, Tsukuba-Shi, Ibaraki, 305-8575, Japan.
Iguchi-Manaka A; Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennnodai, Tsukuba-Shi, Ibaraki, 305-8575, Japan.
Hara H; Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, 1-1-1 Tennnodai, Tsukuba-Shi, Ibaraki, 305-8575, Japan.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2024 Mar 25; Vol. 18 (1), pp. 150. Date of Electronic Publication: 2024 Mar 25.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Hypocalcemia*/chemically induced
Bone Neoplasms*/secondary
Female ; Humans ; Adult ; Aged ; Lapatinib/adverse effects ; Denosumab/adverse effects ; Calcium/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ErbB2 pY -1248 as a predictive biomarker for Parkinson's disease based on research with RPPA technology and in vivo verification.
Autorzy:
Jin M; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
Shi R; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.; School of Psychology, North China University of Science and Technology, Tang'shan, China.
Gao D; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
Wang B; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
Li N; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
Li X; Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd., Ji'nan, China.
Sik A; Institute of Transdisciplinary Discoveries, Medical School, University of Pecs, Pécs, Hungary.; Institute of Clinical Sciences, Medical School, University of Birmingham, Birmingham, UK.; Institute of Physiology, Medical School, University of Pecs, Pécs, Hungary.
Liu K; Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Ji'nan, China.; Engineering Research Center of Zebrafish Models for Human Diseases and Drug Screening of Shandong Province, Ji'nan, China.
Zhang X; School of Psychology, North China University of Science and Technology, Tang'shan, China.
Pokaż więcej
Źródło:
CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Feb; Vol. 30 (2), pp. e14407. Date of Electronic Publication: 2023 Aug 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Parkinson Disease*/diagnosis
Parkinson Disease*/metabolism
Animals ; Mice ; Zebrafish ; Lapatinib/metabolism ; Dopamine/metabolism ; Dopaminergic Neurons/metabolism ; Mice, Inbred C57BL ; Disease Models, Animal
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Different chemical proteomic approaches to identify the targets of lapatinib.
Autorzy:
Kovačević T; Selvita Ltd., Zagreb, Croatia.
Nujić K; Selvita Ltd., Zagreb, Croatia.
Cindrić M; Ruđer Bošković Institute, Zagreb, Croatia.
Dragojević S; Selvita Ltd., Zagreb, Croatia.
Vinter A; Selvita Ltd., Zagreb, Croatia.
Hozić A; Ruđer Bošković Institute, Zagreb, Croatia.
Mesić M; Selvita Ltd., Zagreb, Croatia.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2183809.
Typ publikacji:
Journal Article
MeSH Terms:
Proteomics*
Alkynes*
Lapatinib/pharmacology ; Cell Line ; ErbB Receptors
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Autorzy:
Fakhry MM; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Mattar AA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Egyptian Russian University, Badr 11829, Egypt.
Alsulaimany M; Department of Pharmacognosy & Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina 42353, Saudi Arabia.
Al-Olayan EM; Department of Zoology, College of Science, King Saud University, Riyadh 11495, Saudi Arabia.
Al-Rashood ST; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abdel-Aziz HA; Applied Organic Chemistry Department, National Research Center, Cairo 12622, Egypt.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Nov 06; Vol. 28 (21). Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Protein Kinase Inhibitors*/chemistry
Antineoplastic Agents*/chemistry
Humans ; Molecular Structure ; Structure-Activity Relationship ; Lapatinib/pharmacology ; Drug Screening Assays, Antitumor ; Cell Proliferation ; ErbB Receptors/metabolism ; Molecular Docking Simulation ; Cell Line, Tumor
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer.
Autorzy:
Chen X; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.; Department of Ultrasound, Tianjin Hospital, Tianjin, China.
Li Y; Breast Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Zhou Z; Department of Radiation Oncology and Biochemistry, University of Texas Southwestern Medical Center, Texas, Dallas, USA.
Zhang Y; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Chang L; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Gao X; School of Biomedical Engineering and Technology, Tianjin Medical University, Tianjin, China.
Li Q; Cancer Center, Daping Hospital, Third Military Medical University, Chongqing, China.
Luo H; Cancer Center, Daping Hospital, Third Military Medical University, Chongqing, China.
Westover KD; Department of Radiation Oncology and Biochemistry, University of Texas Southwestern Medical Center, Texas, Dallas, USA.
Zhu J; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Wei X; Department of Diagnostic and Therapeutic Ultrasonography, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 19904-19920. Date of Electronic Publication: 2023 Oct 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms*/diagnostic imaging
Breast Neoplasms*/drug therapy
Humans ; Female ; Lapatinib/pharmacology ; Fluorescein-5-isothiocyanate/therapeutic use ; Receptor, ErbB-2 ; Ultrasonography ; Cell Line, Tumor ; Drug Resistance, Neoplasm
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Autorzy:
Uram Ł; Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Wróbel K; Medical College, Rzeszów University, 1a Warzywna Street, 35-310 Rzeszów, Poland.
Walczak M; Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Szymaszek Ż; Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Twardowska M; Faculty of Chemistry, Rzeszów University of Technology, 6 Powstańcow Warszawy Ave., 35-959 Rzeszów, Poland.
Wołowiec S; Medical College, Rzeszów University, 1a Warzywna Street, 35-310 Rzeszów, Poland.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2023 Aug 30; Vol. 28 (17). Date of Electronic Publication: 2023 Aug 30.
Typ publikacji:
Journal Article
MeSH Terms:
Parasites*
Carcinoma, Non-Small-Cell Lung*
Dendrimers*/pharmacology
Lung Neoplasms*
Glioma*
Humans ; Animals ; Lapatinib/pharmacology ; Paclitaxel/pharmacology ; Fulvestrant ; Caenorhabditis elegans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.
Autorzy:
Lu H; Department of Oncology, Shanghai Pudong New Area People's Hospital, Shanghai, 201200, China.
Chen T; Department of Oncology, Changhai Hospital Affiliated To Navy Medical University, Shanghai, 200433, China.
Wang Y; Department of Oncology, Changhai Hospital Affiliated To Navy Medical University, Shanghai, 200433, China.
He Y; Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China.
Pang Z; Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, China. .
Wang Y; Department of Oncology, Changhai Hospital Affiliated To Navy Medical University, Shanghai, 200433, China. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Feb 16; Vol. 12 (1), pp. 2610. Date of Electronic Publication: 2022 Feb 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Delivery Systems*
Micelles*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brain Neoplasms/*drug therapy
Brain Neoplasms/*secondary
Breast Neoplasms/*pathology
Lapatinib/*administration & dosage
Paclitaxel/*administration & dosage
Animals ; Antineoplastic Combined Chemotherapy Protocols/metabolism ; Biological Transport ; Blood-Brain Barrier/metabolism ; Brain/metabolism ; Brain Neoplasms/pathology ; Disease Models, Animal ; Female ; Humans ; Injections, Intravenous ; Lapatinib/metabolism ; Lapatinib/pharmacology ; Mice ; Paclitaxel/metabolism ; Paclitaxel/pharmacology ; Peptides ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A novel near-infrared EGFR targeting probe for metastatic lymph node imaging in preclinical mouse models.
Autorzy:
Xie D; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Medical School, Nanjing Stomatological Hospital, Nanjing University, Nanjing, China.
Li Y; Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, China.; State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, China.
Shi J; Department of Periodontics, Affiliated Hospital of Medical School, Nanjing Stomatological Hospital, Nanjing University, Nanjing, China.
Zhu YP; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Medical School, Nanjing Stomatological Hospital, Nanjing University, Nanjing, China.
Wang Y; Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, China. .; State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, China. .
Butch CJ; Department of Biomedical Engineering, College of Engineering and Applied Sciences, Nanjing University, Nanjing, China. .; State Key Laboratory of Analytical Chemistry for Life Science, Nanjing University, Nanjing, China. .
Wang Z; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Medical School, Nanjing Stomatological Hospital, Nanjing University, Nanjing, China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2023 Sep 22; Vol. 21 (1), pp. 342. Date of Electronic Publication: 2023 Sep 22.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Squamous Cell*/diagnostic imaging
Carcinoma, Squamous Cell*/drug therapy
Mouth Neoplasms*
Head and Neck Neoplasms*
Humans ; Animals ; Mice ; Lapatinib ; ErbB Receptors ; Lymph Nodes/diagnostic imaging ; Optical Imaging ; Squamous Cell Carcinoma of Head and Neck
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs.
Autorzy:
Maeda S; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan. .
Sakai K; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.; Veterinary Medical Center, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Osaka, Japan.
Kaji K; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Iio A; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Nakazawa M; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Motegi T; Veterinary Medical Center, The University of Tokyo, Tokyo, Japan.
Yonezawa T; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Momoi Y; Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jan 13; Vol. 12 (1), pp. 4. Date of Electronic Publication: 2022 Jan 13.
Typ publikacji:
Clinical Trial, Veterinary; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Lapatinib/*therapeutic use
Piroxicam/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Receptor, ErbB-2/*genetics
Urinary Bladder Neoplasms/*drug therapy
Animals ; Antineoplastic Agents/therapeutic use ; Dog Diseases/drug therapy ; Dogs ; Drug Therapy, Combination/adverse effects ; Female ; Gene Expression Regulation, Neoplastic ; Lapatinib/adverse effects ; Male ; Muscles ; Receptor, ErbB-2/antagonists & inhibitors ; Treatment Outcome ; Urinary Bladder Neoplasms/veterinary
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.
Autorzy:
Zhang Z; Department of Pharmacy, Peking University First Hospital, Beijing, China.
Xu L; Breast Disease Center, Peking University First Hospital, Beijing, China.
Qin N; Department of Radiology, Peking University First Hospital, Beijing, China.
Zhang J; Department of Pathology, Peking University First Hospital, Beijing, China.
Xiang Q; Department of Pharmacy, Peking University First Hospital, Beijing, China.
Liu Q; Breast Disease Center, Peking University First Hospital, Beijing, China.
Cheng Y; Breast Disease Center, Peking University First Hospital, Beijing, China.
Bai Y; Breast Disease Center, Peking University First Hospital, Beijing, China.
Liu Q; Department of Pharmacy, Peking University First Hospital, Beijing, China.
Liu Y; Breast Disease Center, Peking University First Hospital, Beijing, China.
Duan X; Breast Disease Center, Peking University First Hospital, Beijing, China.
Cui Y; Department of Pharmacy, Peking University First Hospital, Beijing, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 Jun; Vol. 12 (12), pp. 1912-1916. Date of Electronic Publication: 2021 May 06.
Typ publikacji:
Case Reports; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms/*drug therapy
Cholangitis, Sclerosing/*chemically induced
Lapatinib/*adverse effects
Vinorelbine/*adverse effects
Breast Neoplasms/pathology ; Female ; Humans ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Middle Aged ; Neoplasm Metastasis ; Vinorelbine/pharmacology ; Vinorelbine/therapeutic use
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HDAC Inhibition Restores Response to HER2-Targeted Therapy in Breast Cancer via PHLDA1 Induction.
Autorzy:
Clayton NS; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Carter EP; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Fearon AE; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Heward JA; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Rodríguez Fernández L; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Boughetane L; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Wilkes EH; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Cutillas PR; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Grose RP; Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 25; Vol. 24 (7). Date of Electronic Publication: 2023 Mar 25.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Female ; Lapatinib/pharmacology ; Lapatinib/therapeutic use ; Histone Deacetylases ; Quinazolines/pharmacology ; Drug Resistance, Neoplasm ; Receptor, ErbB-2/metabolism ; Cell Line, Tumor ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Transcription Factors/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Characterization of Locally Excited and Charge-Transfer States of the Anticancer Drug Lapatinib by Ultrafast Spectroscopy and Computational Studies.
Autorzy:
Vayá I; Departamento de Química/Instituto de Tecnología Química UPV-CSIC, Universitat Politècnica de València, Camino de Vera s/n, 46022, València, Spain.; Unidad Mixta de Investigación UPV-Instituto de Investigación Sanitaria (IIS), La Fe, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.
Andreu I; Departamento de Química/Instituto de Tecnología Química UPV-CSIC, Universitat Politècnica de València, Camino de Vera s/n, 46022, València, Spain.; Unidad Mixta de Investigación UPV-Instituto de Investigación Sanitaria (IIS), La Fe, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.
Lence E; Centro Singular de Investigación en Química Biolóxica e Materiais, Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, 15782, Santiago, de Compostela, Spain.
González-Bello C; Centro Singular de Investigación en Química Biolóxica e Materiais, Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, 15782, Santiago, de Compostela, Spain.
Consuelo Cuquerella M; Departamento de Química/Instituto de Tecnología Química UPV-CSIC, Universitat Politècnica de València, Camino de Vera s/n, 46022, València, Spain.; Unidad Mixta de Investigación UPV-Instituto de Investigación Sanitaria (IIS), La Fe, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.
Navarrete-Miguel M; Instituto de Ciencia Molecular, Universitat de València, P.O. Box 22085, 46071, València, Spain.
Roca-Sanjuán D; Instituto de Ciencia Molecular, Universitat de València, P.O. Box 22085, 46071, València, Spain.
Miranda MA; Departamento de Química/Instituto de Tecnología Química UPV-CSIC, Universitat Politècnica de València, Camino de Vera s/n, 46022, València, Spain.; Unidad Mixta de Investigación UPV-Instituto de Investigación Sanitaria (IIS), La Fe, Hospital Universitari i Politècnic La Fe, Avenida de Fernando Abril Martorell 106, 46026, Valencia, Spain.
Pokaż więcej
Źródło:
Chemistry (Weinheim an der Bergstrasse, Germany) [Chemistry] 2020 Dec 04; Vol. 26 (68), pp. 15922-15930. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/chemistry
Lapatinib*/chemistry
Humans ; Molecular Dynamics Simulation ; Serum Albumin, Human/chemistry ; Spectrum Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial.
Autorzy:
Tsuda M; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Ishiguro H; Breast Oncology Service, Saitama Medical University International Medical Center, Hidaka, Japan.
Toriguchi N; Oncology Products, Medicine Development Unit Japan, Eli Lilly Japan K.K, Kobe, Japan.
Masuda N; Department of Surgery, Breast Oncology, NHO Osaka National Hospital, Osaka, Japan.
Bando H; Breast and Endocrine Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Ohgami M; Department of Pharmacy, Ibaraki Prefectural Central Hospital, Kasama, Japan.
Homma M; Department of Pharmaceutical Sciences, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Morita S; Department of Biomedical Statistics and Bioinformatics. Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yamamoto N; Division of Breast Surgery, Chiba Cancer Center, Chiba, Japan.
Kuroi K; Department of Breast Surgery, Tokyo Metropolitan Health and Hospitals Corporation Ebara Hospital, Tokyo, Japan.
Yanagita Y; Department of Breast Oncology, Gunma Prefectural Cancer Center, Gunma, Japan.
Takano T; Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
Shimizu S; Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Toi M; Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Dec; Vol. 9 (24), pp. 9246-9255. Date of Electronic Publication: 2020 Oct 23.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Breast Neoplasms/*drug therapy
Fasting/*physiology
Lapatinib/*administration & dosage
Trastuzumab/*administration & dosage
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Breast Neoplasms/pathology ; Databases, Factual ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Lapatinib/adverse effects ; Lapatinib/agonists ; Middle Aged ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/antagonists & inhibitors ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
Autorzy:
Ramzy GM; Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211, Geneva, Switzerland.; Translational Research Center in Oncohaematology, 1211, Geneva, Switzerland.
Norkin M; Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne-(EPFL-SV), 1015, Lausanne, Switzerland.
Koessler T; Department of Oncology, Geneva University Hospitals, 1205, Geneva, Switzerland.
Voirol L; Research Center for Statistics, Geneva School of Economics and Management, University of Geneva, 1205, Geneva, Switzerland.
Tihy M; Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1205, Geneva, Switzerland.
Hany D; Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211, Geneva, Switzerland.; Translational Research Center in Oncohaematology, 1211, Geneva, Switzerland.
McKee T; Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1205, Geneva, Switzerland.
Ris F; Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, 1205, Geneva, Switzerland.
Buchs N; Translational Department of Digestive and Transplant Surgery, Geneva University Hospitals and Faculty of Medicine, 1205, Geneva, Switzerland.
Docquier M; iGE3 Genomics Platform, University of Geneva, 1211, Geneva, Switzerland.; Department of Genetics & Evolution, University of Geneva, 1211, Geneva, Switzerland.
Toso C; Department of Visceral Surgery, Geneva University Hospital, 1211, Geneva, Switzerland.
Rubbia-Brandt L; Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1205, Geneva, Switzerland.
Bakalli G; EMLYON Business School, Artificial Intelligence in Management Institute, Ecully, France.
Guerrier S; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211, Geneva, Switzerland.; Research Center for Statistics, Geneva School of Economics and Management, University of Geneva, 1205, Geneva, Switzerland.
Huelsken J; Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne-(EPFL-SV), 1015, Lausanne, Switzerland.
Nowak-Sliwinska P; Molecular Pharmacology Group, School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, CMU, 1211, Geneva 4, Switzerland. .; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211, Geneva, Switzerland. .; Translational Research Center in Oncohaematology, 1211, Geneva, Switzerland. .
Pokaż więcej
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Apr 03; Vol. 42 (1), pp. 79. Date of Electronic Publication: 2023 Apr 03.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Humans ; Precision Medicine/methods ; Lapatinib ; Organoids
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 3526

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies